Ultragenyx Pharmaceutical Inc. $RARE Holdings Lowered by Candriam S.C.A.

Candriam S.C.A. lowered its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 27.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 526,267 shares of the biopharmaceutical company’s stock after selling 201,750 shares during the quarter. Candriam S.C.A. owned approximately 0.56% of Ultragenyx Pharmaceutical worth $19,136,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its position in shares of Ultragenyx Pharmaceutical by 28.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company’s stock worth $116,559,000 after buying an additional 706,519 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in Ultragenyx Pharmaceutical by 81.6% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company’s stock worth $77,815,000 after buying an additional 965,919 shares in the last quarter. Federated Hermes Inc. increased its holdings in Ultragenyx Pharmaceutical by 0.3% in the first quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company’s stock worth $74,419,000 after buying an additional 5,400 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company’s stock valued at $62,291,000 after acquiring an additional 66,394 shares in the last quarter. Finally, Deutsche Bank AG boosted its holdings in Ultragenyx Pharmaceutical by 0.5% during the first quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company’s stock valued at $61,611,000 after acquiring an additional 8,385 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Down 1.9%

Ultragenyx Pharmaceutical stock opened at $32.90 on Friday. The business’s 50-day simple moving average is $31.60 and its 200 day simple moving average is $32.73. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of -5.95 and a beta of 0.30. Ultragenyx Pharmaceutical Inc. has a 12-month low of $25.81 and a 12-month high of $50.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). The company had revenue of $159.93 million during the quarter, compared to the consensus estimate of $167.42 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business’s revenue was up 14.6% compared to the same quarter last year. During the same period last year, the company earned ($1.40) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at approximately $3,095,132.77. The trade was a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the sale, the executive vice president directly owned 73,271 shares of the company’s stock, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 10,456 shares of company stock worth $328,486 in the last ninety days. 5.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

RARE has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Truist Financial cut their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Canaccord Genuity Group decreased their price objective on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $82.75.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.